Literature DB >> 10571801

Cardiac evaluation in hypotension-prone and hypotension-resistant hemodialysis patients.

D Poldermans1, A J Man in 't Veld, R Rambaldi, A H Van Den Meiracker, M A Van Den Dorpel, G Rocchi, E Boersma, J J Bax, W Weimar, J R Roelandt, R Zietse.   

Abstract

BACKGROUND: Hypotension during hemodialysis occurs frequently, but the precise mechanism remains unclear. In this study, the presence of myocardial ischemia and myocardial contractile reserve during infusions of the beta-adrenergic receptor agonist dobutamine was assessed by means of dobutamine-atropine stress echocardiography (DSE) in hypotension-prone (HP) and hypotension-resistant (HR) hemodialysis patients.
METHODS: Eighteen HP patients (age 53 +/- 6 years) were compared with 18 HR patients (age 53 +/- 3 years), matched with respect to the duration of hemodialysis and cardiovascular history. New wall abnormalities during dobutamine stress reflect the presence of myocardial ischemia, whereas the increase in stroke index and cardiac index reflects myocardial contractile reserve.
RESULTS: Wall motion score at rest (1.42 +/- 0.53 vs. 1.44 +/- 0.57) and dobutamine-induced new wall motion abnormalities (4 vs. 3 patients) between HP and HR patients were similar, but responses of cardiac index, stroke index, and systolic blood pressure to do butamine between the two groups were different. Not withstanding a similar cardiac index at rest (2.4 +/- 1.1 liter/min/m2 in HP and 2.8 +/- 1.2 liter/min/m2 in HR patients), dobutamine-induced increments in the cardiac index were considerably smaller in the former (0.8 +/- 1.3 liter/min/m2) than in the latter patients (2.3 +/- 1.6 liter/min/m2, P = 0.002), predominantly because of a progressive decrease in the stroke index in the HP patients.
CONCLUSION: Impaired myocardial contractile reserve rather than ischemia is predominant in HP patients. This impaired myocardial contractile reserve may play a role in the development of hemodialysis-induced hypotension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571801     DOI: 10.1046/j.1523-1755.1999.00737.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Evaluation of intradialytic hypotension using impedance cardiography.

Authors:  Abed Bayya; Dvora Rubinger; David Michael Linton; Sigal Sviri
Journal:  Int Urol Nephrol       Date:  2010-05-07       Impact factor: 2.370

2.  Continuous monitoring of blood pressure by analyzing the blood flow sound of arteriovenous fistula in hemodialysis patients.

Authors:  Yuka Kamijo; Eiichiro Kanda; Hayato Horiuchi; Noriyuki Kounoue; Keisuke Ono; Keizo Maeda; Akane Yanai; Kazuya Honda; Ryuji Tsujimoto; Mai Yanagi; Yoshitaka Ishibashi; Masayuki Yoshida
Journal:  Clin Exp Nephrol       Date:  2017-11-10       Impact factor: 2.801

3.  Dialysis dose and intradialytic hypotension: results from the HEMO study.

Authors:  Finnian R Mc Causland; Steven M Brunelli; Sushrut S Waikar
Journal:  Am J Nephrol       Date:  2013-10-26       Impact factor: 3.754

4.  Effect of intradialytic change in plasma volume on blood pressure in patients undergoing maintenance hemodialysis.

Authors:  Ali-Reza Khalaj; Suzan Sanavi; Reza Afshar; Muhammad-Reza Rajabi
Journal:  J Lab Physicians       Date:  2010-07

5.  Predicting the Appearance of Hypotension During Hemodialysis Sessions Using Machine Learning Classifiers.

Authors:  Juan A Gómez-Pulido; José M Gómez-Pulido; Diego Rodríguez-Puyol; María-Luz Polo-Luque; Miguel Vargas-Lombardo
Journal:  Int J Environ Res Public Health       Date:  2021-02-28       Impact factor: 3.390

Review 6.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

7.  An integrated approach to prognosis using protein microarrays and nonparametric methods.

Authors:  Tanya Knickerbocker; Jiunn R Chen; Ravi Thadhani; Gavin MacBeath
Journal:  Mol Syst Biol       Date:  2007-06-26       Impact factor: 11.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.